Ambry Genetics Announces Launch of Chromosomal MicroArray to Offer Whole Genome Analysis

FOR IMMEDIATE RELEASE

Ambry Genetics
15 Argonaut
Aliso Viejo, CA 92656

Aliso Viejo, CA, June 3, 2009 - Ambry Genetics is pleased to announce the launch of whole-genome Chromosomal Microarray Analysis (CMA), offering the Ambry CMA: 105K Oligo Array, which is designed to identify chromosomal abnormalities associated with over 270 genetic disorders. In a partnership with Baylor College of Medicine, Ambry is now able to provide one of the most comprehensive, clinically-validated genetic tests available using array comparative genomic hybridization. Baylor College of Medicine will equip Ambry with an extensive library of over 20,000 patient samples to reference, and expert cytogeneticist support. Ambry is proud to provide Easy-to-Read reports and free specimen submission kits for all their clients. With the addition of aCGH, Ambry now has one of the most extensive genetic testing menus in the industry.

The Ambry CMA: 105K Oligo Array uses 105,000 probes to cover 270 disease loci, with probes at an average resolution of 30Kb along the human genome to detect copy number variations. A copy number variant (CNV) is a region larger than 1 Kb with a variable copy number compared to a reference genome. Humans usually have two copies of each autosomal region, one per chromosome. If only one or no copy is present, the region harbors a deletion, if more than 2 copies are present, it harbors a duplication. Large regions of the human genome are now known to contain CNVs, many of which contribute to normal human variation and are benign. CNVs may contribute to disease if containing genes whose dosage is important for normal function, (pathogenic CNVs). CNVs are actively being studied and classification is ongoing.

"We are very excited to be able to bring this powerful technology to our clients and their patients. This test can help doctors provide the needed information to solve diagnostic dilemmas. We are hopeful our new service will help many people as the capabilities of this technology become more widely recognized." says Steven Keiles, MS, Vice President and Director of Genetic Services at Ambry Genetics.


About This Report

This report contains forward-looking statements about the Company’s future plans, strategies, objectives, goals and expectations, including projections, estimates, prospects, returns and performance of the Company. Forward-looking statements can be identified by the use of forward-looking terminology such as "may," "will," "should," "expect," "anticipate," "estimate," "intend," "continue," or "believe" or the negatives thereof or other variations thereof or comparable terminology. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. In light of the significant uncertainties inherent in the forward-looking statements made in this report the inclusion of such information should not be regarded as a representation or warranty, express or implied, by the Company or any other person that the objectives and plans of the Company will be achieved.

About Ambry Genetics ®

Ambry Genetics is both College of American Pathologists (CAP)-accredited and Clinical Laboratory Improvement Amendments (CLIA)-certified. Ambry leads in clinical genetic diagnostics and genetics software solutions, combining both to offer the most comprehensive testing menu in the industry. Ambry has established a reputation for sharing data while safeguarding patient privacy, unparalleled service, and responsibly applying new technologies to the clinical molecular diagnostics market. For more information about Ambry Genetics, visit ambrygen.com.

Press Contact:
Aaron Schmidt
Sr Manager, Communications
aschmidt@ambrygen.com
949 457 4679

Search Results

Start your search...